Jasper Therapeutics (NASDAQ:JSPR) Raised to “Hold” at Wall Street Zen

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts have also issued reports on the company. Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a research report on Friday, May 15th. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Finally, Piper Sandler initiated coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.17.

Jasper Therapeutics Price Performance

JSPR opened at $0.70 on Friday. The stock has a market cap of $23.28 million, a P/E ratio of -0.44 and a beta of 3.02. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $2.87. The company has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.85.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. On average, equities research analysts expect that Jasper Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its position in Jasper Therapeutics by 11.2% during the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after purchasing an additional 23,453 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Jasper Therapeutics during the 1st quarter worth approximately $46,000. JPMorgan Chase & Co. raised its stake in shares of Jasper Therapeutics by 1,074.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock worth $361,000 after purchasing an additional 59,547 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at approximately $152,000. Finally, Marshall Wace LLP acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at approximately $281,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.